TriSalus Life Sciences Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -26.7% | -27.3% | +81.3% | -15.3% | -12.8% | +19.4% | +44.3% | -11.7% | -3.1% | +100.9% | -12.0% | |
| – | -28.2% | -36.8% | +111.8% | -14.8% | -13.2% | +21.4% | +51.8% | -12.5% | -3.3% | +111.3% | -12.3% | |
| – | -44.9% | -66.3% | +315.1% | -31.5% | -24.5% | +52.5% | +103.8% | -14.4% | -9.9% | +176.7% | -18.2% | |
| – | -44.9% | -66.3% | +315.1% | -31.5% | – | – | +103.8% | -14.4% | -9.9% | +176.7% | -18.2% | |
| – | +16.4% | +20.3% | +10.0% | +4.4% | +3.6% | +7.2% | +2.2% | -10.2% | +31.2% | -20.5% | +23.9% | |
| – | +56.2% | +14.5% | +18.2% | +16.1% | +1.2% | +2.8% | -8.5% | -13.9% | -6.1% | +22.8% | +11.3% | |
| – | +13.0% | -1.2% | +0.0% | – | – | – | – | – | – | – | – | |
| – | +106.1% | +2.2% | +7.1% | -15.3% | +4.1% | +26.3% | -3.6% | +4.0% | +9.5% | -15.9% | -3.9% | |
| – | +57.8% | -2.0% | -16.7% | -17.3% | +3.1% | +14.9% | -20.7% | +17.0% | +5.4% | +2.5% | -5.2% | |
| – | -7.4% | +3.4% | -11.0% | -17.6% | – | – | +4.2% | +4.9% | +29.5% | +30.5% | +11.9% | |
| – | +78.6% | -30.8% | -15.8% | -26.8% | +57.3% | +23.4% | -32.2% | +98.9% | -20.7% | +41.0% | -11.1% | |
| – | – | – | – | +1.8% | +1.9% | +43.5% | +1.8% | +1.5% | +0.9% | +0.1% | 0.0% | |
| – | -418.9% | – | – | – | – | – | – | – | – | – | -48.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -11.9% | +2.5% | +10.9% | +18.0% | -8.8% | +15.3% | +30.9% | +8.8% | +11.7% | +11.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.